Spikevax developer Moderna (Nasdaq: MRNA) has submitted data to the US Food and Drug Administration with the aim of securing approval for the latest monovalent version of its jab.
The firm is continuing to develop its vaccine to meet the evolving coronavirus threat, with regulators in the UK and Australia the latest to approve its Omicron-directed bivalent vaccine.
Moderna’s more recent version of the COVID-19 vaccine contains spike proteins for the XBB.1.5 sublineage, and comes after the US FDA advised developers to target these variants specifically.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze